[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cognitive-decline\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cognitive-decline":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,99,0,25,[9,50,92,126,155,180,206,236,261,287,334,365,391,422,445,476,503,528,560,580,606,632,669,693,716],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100515939","a-mechanistic-study-to-investigate-tdcs-and-working-memory-in-mci-patients-100515939",false,"NCT05998031","A Mechanistic Study to Investigate tDCS and Working Memory in MCI Patients","AIM","Inclusion Criteria\n\n* Age 60-95 years\n* Montreal Cognitive Assessment (MoCA) score 18 and above (scores will be adjusted for education)\n* Able to receive electrical stimulation\n* Ability to comprehend conversational voices\n* Adequate motor capacity to operate computer mouse and click-button in-scanner\n* Ability to participate in the intervention and attend training sessions Exclusion Criteria\n* Failure to provide informed consent\n* Contraindications to MRI recording (e.g., any kind of ferrous metallic stents or ferrous metal objects in the body, heart valve prosthesis, or other metal implants, claustrophobia, neurostimulation system, defibrillator, pacemaker, or other implanted device)\n* Left-handed, or left hand dominant\n* History of neurological, seizures, and psychiatric disorders, traumatic brain injury, incidence of stroke involving large vessel\n* Terminal illness with life expectancy less than 12 months, as determined by physician\n* Brain tumor or malformation or any foreign body known or previously identified in brain\n* Cancer in active treatment, besides skin cancer\n* Currently on GABAergic or glutamatergic medications, or on calcium or sodium channel blockers, which alter or block the ability of tDCS to facilitate tissue excitability\n* Unable to communicate because of severe hearing loss or speech disorder\n* Severe sensory impairment\n* Inability to communicate in English\n* Severe visual impairment, which would preclude completion of the assessment and\u002For intervention\n* No physical impairment precluding motor response or lying still for an hour in the scanner that could confound study findings\n* Moderate-to-severe depressive symptoms as defined by scoring 10 or above on the Geriatric Depression Scale (GDS)",true,"ALL","60 Years","95 Years",{"count":22,"type":23},110,"ESTIMATED","INTERVENTIONAL",[26],"NA","The current study is a mechanistic study to evaluate working memory gains from application of transcranial direct current stimulation (tDCS) in older adults with mild cognitive impairments (MCI) compared to cognitively healthy control",[29,30],"Cognitive Impairment","Cognitive Decline",[32,33,34,35,36],"Cognitive Aging","Brain Stimulation","functional MRI","Computational Modeling","Finite Element Method (FEM)","RECRUITING","2026-06-25",{"date":40,"type":41},"2026-06-26","ACTUAL",{"date":43,"type":41},"2024-04-24",{"date":45,"type":23},"2029-11-30",{"name":47,"class":48},"University of Florida","OTHER",1,{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":12,"sex":18,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":24,"phases":61,"briefSummary":62,"conditions":63,"keywords":67,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":49},"100642364","using-artificial-intelligence-to-detect-early-signs-of-alzheimers-disease-in-people-with-memory-concerns-100642364","NCT07652931","Using Artificial Intelligence to Detect Early Signs of Alzheimer's Disease in People With Memory Concerns","AHEAD: AI-driven Brain Health for Early Alzheimer's Disease Detection in Individuals With Subjective Cognitive Decline","AHEAD","Inclusion Criteria:\n\n1. Diagnosis of Subjective Cognitive Decline (SCD) according to international diagnostic criteria (Jessen et al., 2014).\n2. Self-experienced persistent decline in cognitive capacity in comparison with a previously normal status and unrelated to an acute event.\n3. Normal age-, gender-, and education-adjusted performance on standardized cognitive tests used to classify mild cognitive impairment (MCI) or prodromal AD.\n4. Age greater than or equal to 40 years.\n5. Native Italian Speaker.\n6. Stable pharmacological treatment for at least 4 weeks prior to enrollment.\n7. Provision of oral and written informed consent to study participation.\n\nExclusion Criteria:\n\n1. Presence of MCI, prodromal AD, or dementia.\n2. Any major systemic, psychiatric, or neurological disturbance.\n3. Medical conditions or substance abuse that could interfere with cognition.\n4. Pacemaker and\u002For other implanted neurostimulation devices in the head\u002Fneck district.\n5. Contraindications to undergoing MRI examination.\n6. Brain damage at routine MRI, including extensive cerebrovascular disorders.\n7. Traumatic or surgical wounds that could determine a risk of infection at the site of non-invasive stimulation.\n8. Scalp alterations that could determine the spread of excessive current from the device.\n9. Known history of epilepsy (due to small risk of seizure induction from rTMS in epileptic patients).\n10. Denial of oral and written informed consent to study participation.","40 Years",{"count":60,"type":23},300,[26],"AHEAD is a prospective, longitudinal, risk-stratified single-arm interventional study enrolling 300 patients with Subjective Cognitive Decline (SCD) at IRCCS San Raffaele Hospital, Milan, Italy.\n\nThe study uses artificial intelligence (AI) to integrate multimodal data - including MRI, EEG, Optical Coherence Tomography (OCT), neuropsychological assessments, and plasma biomarkers - to identify individuals with underlying Alzheimer's disease (AD) biology and predict cognitive progression.\n\nOnly participants found to be AD plasma biomarker positive (SCD+) undergo longitudinal follow-up at 12 and 24 months. Participants classified as high risk additionally receive a 6-month personalized multidisciplinary intervention combining high-frequency transcranial magnetic stimulation (TMS), digital cognitive training, structured physical exercise, and targeted management of modifiable vascular and behavioral risk factors.",[64,65,66,30],"Subjective Cognitive Decline","Alzheimer Disease","Mild Cognitive Impairment",[64,68,69,70,71,72,73,74,75,76,77,78,79,80,81],"Alzheimer's disease","Artificial Intelligence","Transcranial Magnetic Stimulation","Plasma biomarkers","p-tau217","MRI","EEG","Optical Coherence Tomography","Cognitive Training","Physical Exercise","Brain Health","APOE","Machine Learning","Deep Learning","NOT_YET_RECRUITING","2026-06-11",{"date":85,"type":41},"2026-06-17",{"date":87,"type":23},"2026-08-01",{"date":89,"type":23},"2029-08-01",{"name":91,"class":48},"IRCCS San Raffaele",{"id":93,"slug":94,"hasResults":12,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":12,"sex":18,"minAge":98,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":24,"phases":101,"briefSummary":102,"conditions":103,"keywords":110,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":125},"100608933","evaluating-health-outcomes-of-ai-based-fitness-wearables-and-app-programs-in-older-adults-living-alone-with-cognitive-decline-100608933","NCT07207993","Evaluating Health Outcomes of AI-Based Fitness Wearables and App Programs in Older Adults Living Alone With Cognitive Decline","Inclusion Criteria:\n\n* Participant must be at least 65 years of age older\n* Participant must be living alone in the U.S. for the next 6 months\n* Participant must have report mild cognitive decline \\[We will use a short self-report AD8 measure of cognitive concerns. Those scoring positive on the AD8 (≥2) will qualify as mild cognitive decline\\];\n* Participant must own an Android\u002FApple smartphone\n* Participant must have access to internet or Wi-Fi access\n* Participant must be capable of engaging in some PA as determined by the PA Readiness Questionnaire or physician approval\n* Participant must currently participate in weekly moderate-to-vigorous PA (MVPA) or less than 150 minutes\n* Participant must have basic English communication skills.\n\nExclusion Criteria:\n\n* Foreign residents or visitors","65 Years",{"count":100,"type":23},64,[26],"The overarching goal of our research is to develop personalized and accessible healthy aging lifestyle interventions aimed at promoting physical activity (PA) and improving health among community-dwelling older adults living alone with cognitive decline (LACD). To achieve this goal, the purpose of this project is to determine whether wearable and app-based mHealth intervention component(s) will contribute to increased PA and improved health outcomes in older adults LACD. Our specific aims are to: identify and evaluate mHealth intervention components that practically and significantly contribute to enhanced mechanistic outcomes (e.g., self-efficacy, outcome expectations) and increased PA (primary outcome) in older adults LACD over a 6-month period; determine the optimal combinations of intervention components for future efficacy testing; elucidate the mechanism of behavioral change (MoBC) and potential outcomes of these intervention components, namely, the mediating effects of MoBC variables (e.g., self-efficacy, outcome expectations) on the relationship between intervention components and change in PA. The first two aims are primary and fully-powered. The third aim is exploratory. The aims will support a refined, data-driven intervention design for a subsequent larger trial.",[104,105,106,107,30,108,109],"Older Adults With Cognitive Decline","Older Adults","AI-Based Fitness","Wearables","Physical Activity","Physical Inactivity",[111,112,106,108,109,113,114,115],"Older adults","Cognitive decline","Living alone with cognitive decline","LACD","U.S Older adults","2026-06-10",{"date":118,"type":41},"2026-06-15",{"date":120,"type":41},"2026-06-08",{"date":122,"type":23},"2028-06-08",{"name":124,"class":48},"The University of Tennessee, Knoxville",2,{"id":127,"slug":128,"hasResults":12,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":24,"phases":135,"briefSummary":136,"conditions":137,"keywords":141,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":49},"100617518","community-based-social-connection-intervention-program-to-improve-cardiovascular-and-brain-health-100617518","NCT07319663","Community-Based Social Connection Intervention Program to Improve Cardiovascular and Brain Health","Quasi-experimental Community-Based Social Connection Intervention Program to Improve Cardiovascular and Brain Health in Older Adults Living in Rural Ecuador","Inclusion Criteria:\n\nAge 60 years or older Permanent resident of the community for at least one year Able to provide written informed consent Able to participate in community activities and home-based assessments No plans to relocate during the 12-month follow-up\n\nExclusion Criteria:\n\nSevere disability that prevents participation in study activities Diagnosed dementia, major psychiatric illness, or severe cognitive impairment History of stroke with significant functional limitation Terminal illness or medical condition that precludes follow-up\n\n\\-",{"count":134,"type":23},500,[26],"This study evaluates the effectiveness of a community-based social connection intervention program (SCIP) designed to reduce social isolation and loneliness and improve cardiovascular and brain health among older adults living in rural Ecuador. Loneliness and social isolation are recognized risk factors for poor cardiovascular outcomes, cognitive decline, depression, and reduced quality of life. However, evidence from low- and middle-income countries, particularly in rural Latin American settings, remains limited. This protocol describes a quasi-experimental, longitudinal study conducted in three rural villages that have been part of a long-standing population-based cohort.\n\nThe intervention will be implemented in one community and compared with two similar communities that will continue receiving usual community activities. SCIP consists of three components: (1) monthly community activities and educational talks designed to promote social participation; (2) monthly peer-support group sessions facilitated by trained personnel; and (3) individualized home-based coaching delivered twice per month, incorporating principles of Social Cognitive Theory and Cognitive Behavioral Therapy. The program aims to strengthen social networks, enhance coping skills, and promote healthier behaviors.\n\nParticipants aged 60 years and older will be enrolled and followed for 12 months. Assessments will occur at baseline, 6 months, and 12 months. Primary outcomes include changes in social isolation (Lubben Social Network Scale-6) and loneliness (De Jong Gierveld Scale). Secondary outcomes include cardiovascular health (Life's Essential 8), sleep quality (Pittsburgh Sleep Quality Index), cognitive performance (Montreal Cognitive Assessment), depressive symptoms (DASS-21), and quality of life (SF-36). Exploratory outcomes include incident stroke, cardiovascular events, and mortality, monitored through ongoing community surveillance.\n\nThis study will generate evidence on the feasibility and impact of a culturally adapted, community-based intervention to promote social connection and healthy aging in a resource-limited rural setting. Findings may inform scalable public health strategies for older adults in similar contexts.",[138,139,140,30],"Social Isolation in Older Adults","Loneliness","Stroke",[142,139,143,144,145,146],"Social isolation","Social support","Community Health Services","Rural population","Aged","2026-06-09",{"date":83,"type":41},{"date":150,"type":41},"2026-06-01",{"date":152,"type":23},"2027-06-01",{"name":154,"class":48},"Universidad de Especialidades Espiritu Santo",{"id":156,"slug":157,"hasResults":12,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":17,"sex":18,"minAge":163,"maxAge":98,"enrollmentInfo":164,"targetDuration":4,"studyType":24,"phases":166,"briefSummary":167,"conditions":168,"keywords":169,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":173,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":125},"100602780","exercise-adherence-and-cognitive-decline-phase-2-100602780","NCT07127965","Exercise Adherence and Cognitive Decline: Phase 2","Exercise Adherence and Cognitive Decline: A Goal-setting and Exercise Intensity Intervention Collaboratively Developed With the Black Community","MOVE","Inclusion Criteria:\n\n* \\\u003C3 incorrect responses on the Pfeiffer Mental Status Questionnaire\n* Ages 45 to 65\n* Consent to be randomized to conditions\n* Planning to remain in the Denver metro area for the next 14 months\n* Identify as Black or African American\n\nExclusion Criteria:\n\n* Currently physically active (i.e., \\>90 min\u002Fweek of moderate PA or \\>40 min\u002Fweek of vigorous PA consistently for the past 6 months)\n* On antipsychotic medications or currently under treatment for any serious psychiatric disorder including Alzheimer's or dementia\n* Inability to walk 3 blocks without chest pain, shortness of breath, or lightheadedness\n* Inability to climb 2 flights of stairs without chest pain, shortness of breath, or lightheadedness\n\nPCP Exclusion Criteria:\n\n* Answers \"yes\" to 1 or more of the 7 general questions of the PAR-Q+ and answers yes to any of the follow up questions.\n* Blood pressure at baseline is greater than 160\u002F100\n* Blood pressure at baseline is between 140\u002F90 - 160\u002F100 and the participant is currently taking blood pressure medication\n* Blood pressure \\> 210\u002F90 mmHg (for men) or \\> 190\u002F90 mmHg (for women) immediately after exercise","45 Years",{"count":165,"type":23},226,[26],"The purpose of this study is to conduct a test of a goals-based program to help people exercise more. This program was designed for individuals aged 45-65 from the Black community. Low levels of physical activity are related to health problems such as heart disease, diabetes, and cognitive decline. People of color are more negatively impacted by these conditions and have also historically been underrepresented by research seeking to increase physical activity. The investigators have developed this goals-based exercise promotion program with the help of a Black-led community-based organization (The Gyedi Project) and a Community Advisory Board made up of stakeholders in the Black community.",[30],[170,171,172,30],"Goals","Goal Difficulty","Exercise Intensity",{"date":83,"type":41},{"date":175,"type":41},"2025-11-05",{"date":177,"type":23},"2028-08-31",{"name":179,"class":48},"University of Colorado, Boulder",{"id":181,"slug":182,"hasResults":12,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":17,"sex":18,"minAge":188,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":24,"phases":190,"briefSummary":191,"conditions":192,"keywords":194,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":199,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":49},"100555066","polyphenols-and-cognitive-decline-100555066","NCT06507254","Polyphenols and Cognitive Decline","MAEVE: Microbiota Mediated Flavonoid Metabolites for Cognitive Health","MAEVE","Inclusion Criteria:\n\n* 50+ Years of age\n* Male or Female\n* At enhanced risk of Alzheimer's Disease (defined as family history of AD, 1st degree family member)\n* Habitually consume suboptimal diets such as typical Western Diet (i.e., high in animal products, refined carbohydrates and processed food)\n* Able to communicate well in English\n\nExclusion Criteria:\n\n* Vegan or Vegetarian\n* Presence of cognitive impairment at the time of recruitment into the study as measured by the Mini Mental Status Exam (MMSE, score 25-30) and Clinical Dementia Rating (CDR, score=0).\n* Pre-existing psychosis or psychiatric conditions\n* Currently receiving treatment for dementia\n* History of alcohol and\u002For substance abuse\u002Fdependence as determined by a positive endorsement on the MINI+\u002F If the MINI+ is positive for alcohol or drug dependence, or abuse, the participants will be excluded.\n* Heavy use of tobacco (greater than 1\u002F2 pack per day)\n* History of cerebrovascular events\n* Existing allergies to berry fruits\n* Use of oral\u002FIV antibiotics in the last 3 months. Use of probiotics in the last 1 month.\n* Recent Changes (last 3 months) in the use of psychoactive medications or other medications that interfere with the measured outcomes.\n* Frailty, malnutrition, or food allergy\u002Fintolerance requiring special diets.\n* Body weight at enrollment greater than 400lbs due to weight restrictions on the MRI table.\n* Women who are pregnant, lactating, or postpartum for less than 6months.\n* Women of childbearing age who are not practicing birth control or are planning to get pregnant during the study.\n\nUnable to safely participate in the MRI (claustrophobia, presence of devices affected by MRI such as pacemakers, neurostimulators, metallic foreign body, etc.)\n\n* Chronic Pain","50 Years",{"count":60,"type":23},[26],"Globally, populations are aging thereby increasing healthcare burden, overall cognitive impairment, and dementia including Alzheimers diseases (AD). The lack of effective treatments makes it essential to develop new strategies for healthy cognitive aging, including interventions to slow or prevent cognitive decline. A traditional Mediterranean diet, rich in polyphenols (PPs), may prevent or delay the onset of cognitive dysfunction in older adults, preserving healthy brain structure and function, and lowering the risk of AD. These effects, mediated in part by gut microbiome-derived PP metabolites, highlight the role alterations in the brain-gut microbiome system play in neurodegeneration. Moreover, high levels of circulating phenyl-y-valerolactones, neuroprotective compounds, exclusively produced by gut microbiota from flavan-3-ol-rich foods (e.g., cocoa, tea, berries) are associated with delaying the onset of cognitive dysfunction in older adults. Intake of such PPs can also change gut microbial composition and function, altering the physiology of the hosts secondary bile acid (BA) pool, affecting regulatory and signaling functions in the brain as well as cognitive decline and AD. The investigators hypothesize that, in older adults with enhanced AD risk, dietary intake of PPs maintains healthier brain features and cognitive function, and that this beneficial effect is mediated by gut microbiota metabolites of PPs and BAs.\n\nIn this multi-PI application by leaders in the field of brain-gut microbiome interactions, the investigators will conduct a year-long, multi-center, randomized double-blind placebo-controlled study in 300 older adults in the United States (validation sample of 100 from Northern Ireland) who are at enhanced risk of developing AD. Ultimately, the investigators will establish the protective effects of regular dietary PP intake on cognitive function and on brain-gut microbiome interactions, ideally allowing the development of effective dietary regimes to prevent of delay the onset of AD in at-risk elderly, thereby reducing cognitive decline and healthcare costs.\n\nParticipants will be asked to provide information about their diet, mood, and behaviors via food diaries, physical body measures (e.g. height, weight, etc.), and online questionnaires collected before each in-clinic appointment, as well as monthly online questionnaires. MR imaging will be collected on participants to assess neurocognitive changes as a result of the supplement. Participants will be asked to provide both stool and blood samples. Participants will be randomly assigned to either the Juice Plus+ intervention group or the placebo treatment group and then asked to take their respective supplement 4 pills twice a day. All participants will be asked to come in for 4 in-clinic appointments, including 3 brain MRI scans and 3 cognitive testing appointments, collect 3 stool samples with corresponding diet diaries, and provide 3 blood samples over the course of 12 months. Participants will also meet with a nutritionist 3 times over the 12 months to discuss diet to ensure study eligibility and any questions about the supplement.",[30,193],"Cognitive Dysfunction",[195,196,197,198],"Polyphenols","Mediterranean Diet","Gut Microbiome","Alzheimers Disease",{"date":83,"type":41},{"date":201,"type":41},"2025-01-09",{"date":203,"type":23},"2029-12-31",{"name":205,"class":48},"University of California, Los Angeles",{"id":207,"slug":208,"hasResults":12,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":213,"targetDuration":4,"studyType":215,"phases":4,"briefSummary":216,"conditions":217,"keywords":220,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":232,"leadSponsor":234,"locationsCount":49},"100637415","effects-of-comprehensive-community-support-programs-on-cognitive-function-and-quality-of-life-in-older-adults-100637415","NCT07610109","Effects of Comprehensive Community Support Programs on Cognitive Function and Quality of Life in Older Adults","THE EFFECTS OF COMPREHENSIVE COMMUNITY SUPPORT PROGRAMS FOR THE ELDERLY ON COGNITIVE FUNCTIONS AND QUALITY OF LIFE: THE VEFAHANE MODEL","Inclusion Criteria:\n\n* Elderly individuals aged 60 and over who attend or will attend Vefahane Life Center\n* Able to cooperate,\n* Individuals who speak Turkish\n* Individuals who are literate\n\nExclusion Criteria:\n\n* Individuals previously diagnosed with dementia,\n\n  * Individuals with neurological and psychiatric diagnoses that affect cognitive skills,\n  * Individuals receiving occupational therapy interventions aimed at improving cognitive skills within the center,\n  * Individuals with illnesses that prevent participation in the activity program (cancer, cardiovascular instability, etc.),\n  * Individuals with severe visual and hearing loss that hinders communication.",{"count":214,"type":23},120,"OBSERVATIONAL","This prospective observational study aims to investigate the effects of a multidomain community-based support program on cognitive function and quality of life in older adults attending the Vefahane Life Center in Istanbul, Türkiye. The study will compare elderly individuals actively participating in community-based social, cognitive, physical, and supportive activities with individuals registered at the center but not actively participating during the study period. Participants will undergo neuropsychological and psychosocial assessments at baseline and after 3 months. The primary outcome is change in global cognitive performance measured by the Mini Mental State Examination (MMSE). Secondary outcomes include memory, executive functions, depression, neuropsychiatric symptoms, and quality of life measures.",[30,218,219],"Aging","Quality of Life",[221,222,223,224,225,226,227],"older adults","aging","cognitive rehabilitation","cognitive function","community-based intervention","social wellbeing","social participation","2026-05-20",{"date":230,"type":41},"2026-05-27",{"date":228,"type":41},{"date":233,"type":23},"2026-12-30",{"name":235,"class":48},"Istanbul Medipol University Hospital",{"id":237,"slug":238,"hasResults":12,"nctId":239,"briefTitle":240,"officialTitle":240,"acronym":241,"eligibilityCriteria":242,"healthyVolunteers":12,"sex":18,"minAge":243,"maxAge":4,"enrollmentInfo":244,"targetDuration":4,"studyType":215,"phases":4,"briefSummary":246,"conditions":247,"keywords":248,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":49},"100283625","identification-of-epigenetic-risk-factors-for-ischemic-complication-during-the-tavr-procedure-in-the-elderly-100283625","NCT02972008","Identification of Epigenetic Risk Factors for Ischemic Complication During the TAVR Procedure in the Elderly","METHYSTROKE","Inclusion Criteria:\n\n* Patients over 70 years with severe aortic stenosis requiring percutaneous aortic valve replacement (TAVI)\n\nExclusion Criteria:\n\n* Patient contraindicated for the TAVI procedure\n* Patient with a pace-maker\n* Patient with contra-indication for cerebral MRI\n* Ongoing cancer\n* Patient already involved in therapeutic research\n* Major persons under protection of justice.","70 Years",{"count":245,"type":23},542,"Over the past ten years, the number of endovascular procedures has increased by 5% per year in Europe with the development of interventional cardiology, such as percutaneous coronary angioplasty, aortic valve replacements (TAVR), and vascular endoprosthesis.\n\nThe neurological lesions detected on cerebral MRI caused by these endovascular procedures are frequent with an incidence of about 30-70%. These events, although subclinical, have an impact on morbidity and mortality and especially on long-term cognitive decline.\n\nTAVR is the reference treatment for symptomatic elderly patients with stenosis of the aortic valve, considered by a multidisciplinary \"Heart Team\" as at high surgical risk due to comorbidities, age and high perioperative risk scores ( Euroscore 2 and STS scores). Despite the net clinical benefit, an increase of silent neurological events was detected on post-procedural cerebral MRI with an incidence of approximately 70%.\n\nThe epigenetic involvement in the occurrence of ischemic cerebral lesions is still largely unknown. Epigenetic mechanisms, such as DNA methylation, can be associated with aging processes and modulate the risk of developing cerebrovascular pathologies. They are likely to provide new biomarkers that predict the risk of brain damage.\n\nHypomethylation of leukocyte DNA is directly related to atherosclerosis in humans. This hypomethylation of DNA would represent an easily measurable marker reflecting the presence and progression of atherosclerosis. Because atherosclerotic lesions often precede the clinical manifestation of ischemic cardiovascular disease, such as ischemic heart disease and stroke, DNA hypomethylation could be used to identify individuals at risk for cerebrovascular events.\n\nThe investigator hypothesize that hypomethylation of leukocyte DNA can predict the risk of developing new ischemic brain lesions especially after a TAVI procedure.",[30,140],[249,250,251,252],"Aortic stenosis","Transaortic valve replacement","stroke","Epigenetic",{"date":254,"type":41},"2026-05-22",{"date":256,"type":41},"2017-03-09",{"date":258,"type":23},"2027-02",{"name":260,"class":48},"University Hospital, Lille",{"id":262,"slug":263,"hasResults":12,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":12,"sex":18,"minAge":268,"maxAge":269,"enrollmentInfo":270,"targetDuration":4,"studyType":215,"phases":4,"briefSummary":272,"conditions":273,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":49},"100411294","cognitive-status-after-removal-of-skull-base-meningioma-100411294","NCT04635657","Cognitive Status After Removal of Skull Base Meningioma","Pre and Post-Operative Cognitive Status in Patients Undergoing Surgery for Resection of Meningioma Associated With the Frontal and Temporal Lobes","Inclusion Criteria:\n\n* Subject has a meningioma associated with the frontal or temporal lobes\n* Subject is scheduled to undergo open craniotomy or Endoscopic Endonasal surgery\n* Subject is 18 years of age or older\n* The subject must in the investigator's opinion, be psychosocially, mentally, and physically able to fully comply with this protocol including the required follow-up visits, the filling out of required forms, and have the ability to understand and give written informed consent\n* Previous surgery will not exclude the patient as a new baseline cognitive evaluation will occur.\n\nExclusion Criteria:\n\n* Patient is a prisoner\n* Patient is 90 years of age or older\n* Pregnant women\n* Previous radiation to the brain","18 Years","89 Years",{"count":271,"type":23},50,"The purpose of this prospectively enrolling trial is to assess long-term cognitive outcomes of patients undergoing surgery for resection of a meningioma associated with the frontal and temporal lobes.",[274,275,276,277,29,30,278],"Meningioma","Skull Base Meningioma","Frontal Meningioma","Temporal Meningioma","Post-Surgical Cognition","2026-05-19",{"date":254,"type":41},{"date":282,"type":41},"2019-12-10",{"date":284,"type":23},"2028-12-31",{"name":286,"class":48},"Ohio State University",{"id":288,"slug":289,"hasResults":12,"nctId":290,"briefTitle":291,"officialTitle":291,"acronym":292,"eligibilityCriteria":293,"healthyVolunteers":17,"sex":294,"minAge":295,"maxAge":19,"enrollmentInfo":296,"targetDuration":4,"studyType":24,"phases":297,"briefSummary":298,"conditions":299,"keywords":307,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":327,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":49},"100639704","algal-lutein-against-decline-of-intellectual-nimbleness-100639704","NCT07600567","Algal Lutein Against Decline of Intellectual Nimbleness","ALADIN","Inclusion Criteria:\n\n* Females\n* Age 48-60 years\n* Postmenopausal status (natural menopause, up to 5 years after menopause)\n* waist circumference ≥ 88 cm\n\nExclusion Criteria:\n\n* Diagnosis of dementia or cognitive impairment\n* Use of hormone replacement therapy within the last 6 months\n* Advanced age-related macular degeneration\n* History of major untreated neurological or psychiatric disorders (including depression, Parkinson's disease, Alzheimer's disease, psychiatric disorders, stroke within the last 3 months)\n* Presence of chronic diseases, including: diabetes mellitus (type 1 or 2), lipid disorders, cardiovascular diseases, thyroid diseases, anemia, liver diseases, gastrointestinal disorders, or cancer within the last 5 years\n* Use of anti-inflammatory medications or medications targeting lipid or carbohydrate metabolism within the last 3 months\n* Alcohol consumption \\> 100 g per week\n* Use of lutein-containing supplements","FEMALE","48 Years",{"count":60,"type":23},[26],"Lutein is a xanthophyll pigment found in photosynthesizing organisms. Its beneficial effects on health, including brain function and visual performance, have been recognized for many years. However, to date, only a limited number of well-designed human intervention studies have been published regarding the effects of incorporating lutein into the daily diet (as humans are unable to synthesize lutein endogenously). Unfortunately, within the Western dietary pattern, the average daily intake of lutein is approximately 1.7 mg, whereas achieving health benefits- such as reducing the risk of age-related macular degeneration and cataract, as well as neurodegenerative diseases- requires an intake of 6 to 14 mg per day.\n\nIn light of the above, it is therefore justified to enrich the daily diet with products that are sources of lutein. Unfortunately, the consumption of dark green vegetables- the richest dietary source of lutein-remains insufficient. Lutein preparations currently available on the market are extracted from marigold or calendula flowers. However, lutein production from these raw materials requires greater water consumption and land use, which is not aligned with the principles of sustainable development. An alternative approach involves the production of lutein preparations from microalgae (from species approved as food by the European Food Safety Authority, EFSA), as the rate of lutein production from microalgae is three to six times higher than that from marigold flowers.\n\nTaking the above into account, the primary objective of this project is to evaluate the dose-response relationship in establishing the anti-aging mechanism of action of lutein derived from microalgae.\n\nAs part of the project, a six-month randomized, placebo-controlled trial is planned. The study will include 300 polish women (aged 48-60 years), after natural menopause, with visceral obesity (waist circumference ≥ 88 cm). In order to enable the inclusion of such a large study population, the research team will conduct intensified recruitment efforts for several months prior to the initiation of the dietary intervention.\n\nParticipants who meet the inclusion criteria will be randomly assigned to one of three groups: lutein supplementation at a dose of 6 mg (n = 100), lutein supplementation at a dose of 14 mg (n = 100), or placebo (n = 100). The volunteers will be instructed to take the prescribed preparation daily for 180 days. All preparations will be identical in appearance, taste, and smell.\n\nAll volunteers expressing willingness to participate in the experiment will be asked to provide written informed consent prior to enrollment in the study.\n\nThe study will be conducted in accordance with the previously calculated sample size (n = 300 postmenopausal women with visceral obesity). In order to obtain a homogeneous study population, appropriate inclusion and exclusion criteria will be applied.\n\nConducting the research in such a large and homogeneous group will enable the generation of high-quality scientific evidence identifying the dose of microalgae-derived lutein that allows for the determination of its anti-aging mechanism of action. It will also be possible to elucidate the potential role of short-chain fatty acids (SCFAs) in feces in this process, which may represent a significant novelty in this field of research.\n\nThe study will contribute to the development of new knowledge regarding the anti-aging properties of lutein derived from microalgae in populations vulnerable to cognitive impairment (postmenopausal women). However, microalgae-derived lutein may be used as a dietary supplement not only in the studied group but also in the general population.\n\nThe specific objectives are as follows:\n\n* To assess the effect of lutein derived from microalgae (at doses of 6 mg and 14 mg) on the concentration of brain-derived neurotrophic factor (BDNF), inflammatory markers, cardiometabolic parameters, fecal short-chain fatty acid (SCFA) concentrations, and cognitive function in postmenopausal women with visceral obesity.\n* To evaluate adherence to lutein supplementation recommendations (by assessing macular pigment optical density).\n* To determine whether supplementation with microalgal lutein increases fecal SCFA concentrations and whether SCFAs may act as mediators in improving inflammatory markers and cognitive function in postmenopausal women with visceral obesity.\n* To determine whether supplementation with microalgal lutein (at doses of 6 mg and 14 mg) affects changes in selected gut bacterial populations and β-glucuronidase enzymatic activity in postmenopausal women with visceral obesity.\n* To analyse the association between polymorphisms in genes related to lutein metabolism and transport in the body and the effectiveness of supplementation with this compound.\n* To identify dietary behaviour patterns associated with high exposure to bisphenol A (BPA) and the presence of inflammation in postmenopausal women with visceral obesity.",[300,30,301,302,303,304,305,306],"Menopausal Syndrome","Obesity & Overweight","Menopause","Inflamation","Gut Dysbiosis","Bisphenol A","Cardio Vascular Disease",[308,309,310,311,312,313,314,315,316,317,318,319,320,321,322,323,324,325],"menopausal syndrome","cognitive decline","obesity","menopause","inflammation","dysbiosis","bisphenol A","gut microbiota","BNDF","intellectual nimbleness","beta-glucuronidase","lutein","supplementation","micro-algae","gene polimorfism","eye vision","chlorella","sustainable development","2026-05-13",{"date":228,"type":41},{"date":329,"type":23},"2026-05-01",{"date":331,"type":23},"2027-04-30",{"name":333,"class":48},"Poznan University of Life Sciences",{"id":335,"slug":336,"hasResults":12,"nctId":337,"briefTitle":338,"officialTitle":338,"acronym":339,"eligibilityCriteria":340,"healthyVolunteers":12,"sex":18,"minAge":268,"maxAge":4,"enrollmentInfo":341,"targetDuration":4,"studyType":24,"phases":343,"briefSummary":345,"conditions":346,"keywords":351,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":4},"100485768","phase-1-minocycline-in-neurocognitive-outcomes---sickle-cell-disease-100485768","NCT05605366","Minocycline In Neurocognitive Outcomes - Sickle Cell Disease","MINO-SCD","Inclusion Criteria:\n\nAdults (age ≥ 18 years old) with SCD (HbSS and HbS-β0thalassemia genotypes only) who are followed at the University of Cincinnati Medical Center's SCD clinic are eligible to participate. As hydroxyurea is the standard-of-care in SCD, individuals on hydroxyurea will be included\n\nExclusion Criteria:\n\n1. adults with other SCD genotypes (HbSC or HbS- β+thalassemia),\n2. individuals with a history of overt stroke or other known neurological disorder,\n3. premature birth before 30 weeks gestation,\n4. monthly therapy with chronic blood transfusions,\n5. coexisting autoimmune condition due to an elevated risk for autoimmune-related complications with tetracyclines,\n6. tetracycline allergy.\n7. Women who are pregnant or breast-feeding",{"count":342,"type":23},30,[344],"PHASE1","Sickle cell disease (SCD) is a common, inherited blood disorder that primarily affects people of African Ancestry. It has a lot of complications including neurological complications. The neurological complications of SCD are particularly devastating and lead to cognitive decline even in the absence of overt brain injury. In such cases, it is thought that inflammation in the brain maybe partly responsible for the cognitive decline.\n\nThe main reasons for this research study are to see 1) how safe and 2) how well minocycline works to try to stop\u002Freverse cognitive decline in people with SCD. People with SCD are at risk for changes in their brain over time that can cause problems with learning, memory, and attention. Part of the reason for this is inflammation within the brain. Minocycline may be able to stop these brain changes by stopping this brain inflammation.\n\nMinocycline is a second-generation tetracycline antibiotic that has been shown to both inhibit neuroinflammation and improve cognitive function in a variety of neurodegenerative and psychiatric disorders but has not yet been studied in SCD. We are proposing here, a pilot double-blinded, randomized controlled trial to examine the tolerability and early efficacy of minocycline in adults with SCD at two dosing regimens (200 mg and 300 mg daily) versus placebo over one year. Participants will undergo a neuropsychological exam using the NIH Toolbox Cognition Battery at both study enrollment and exit (after one year) to assess for changes\u002Fstability of cognition. Participants will receive monthly phone calls\u002Ftext messages to assess for adverse events and will be seen every three months for pill counts and routine laboratory monitoring. The primary outcome will be a comparison of adverse events across the two dosing strategies versus placebo. Early evidence for cognitive benefit will also be assessed from the results of the NIH Toolbox.",[347,29,30,348,193,349,350],"Sickle Cell Disease","Cognitive Change","Cognitive Deficit","Neuroinflammatory Response",[352,353,354,355],"sickle cell disease","benign hematology","cognitive dysfunction","neuroinflammation","2026-05-11",{"date":358,"type":41},"2026-05-14",{"date":360,"type":23},"2026-12-01",{"date":362,"type":23},"2028-06-15",{"name":364,"class":48},"University of Cincinnati",{"id":366,"slug":367,"hasResults":12,"nctId":368,"briefTitle":369,"officialTitle":369,"acronym":370,"eligibilityCriteria":371,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":372,"enrollmentInfo":373,"targetDuration":4,"studyType":24,"phases":374,"briefSummary":375,"conditions":376,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":49},"100442999","effect-of-hypoxic-conditioning-on-cerebrovascular-health-in-the-elderly-100442999","NCT05048680","Effect of Hypoxic Conditioning on Cerebrovascular Health in the Elderly","HYPOXAGE","Inclusion Criteria:\n\n* 60 to 80 years of age;\n* Being physically inactive (less than 150 min\u002Fweek of moderate to intense physical activity);\n* No chronic cardiovascular, respiratory, metabolic or neuromuscular disease counterindicating an exercise training or hypoxic conditioning program;\n* Health coverage;\n* Being able to provide written fully informed consent.\n\nExclusion Criteria:\n\n* Body-mass index \\>30 kg\u002Fm2;\n* Smoking (\\> cigarettes\u002Fday);\n* Alcohol use (\\> 10g\u002Fday);\n* Mental disorder or history of mental disorder;\n* Beta-blockade treatment;\n* Inability or refusal to provide informed consent;\n* No health coverage\n* People exceeding the annual ceiling of allowances received as a result of their participation in other clinical trials;\n* People deprived of freedom by judicial or administrative decision;\n* People subject to legal protection, who cannot be included in clinical trials.","80 Years",{"count":100,"type":23},[26],"In line with the ever-growing aging of Western populations, the development of preventive strategies to slow down the effects of aging on cardiovascular health represents a major challenge in order to preserve functional capacities and a sufficient quality of life in the elderly. The alteration of vascular function (at the cerebral and systemic level) with aging is an important feature in the clinical picture including a decrease in physical and cognitive capacities. Although physical activity is recognized as an essential means of combating the effects of aging, optimizing its effects by defining the most effective strategies of practice remains a key objective. Offering alternative interventions to exercise training is also necessary for people who are unwilling or unable to engage in a physical activity program. In this context, hypoxic conditioning, alone or in conjunction with rehabilitative exercise training, is a new therapeutic modality with strong preclinical validity, in particular from a cardiovascular standpoint, and used in other pathologies to improve cardiovascular function and exercise performance and quality of life. Our aim is, therefore, to investigate the effect of hypoxic conditioning (alone or in conjunction with exercise training) on cerebrovascular health in the elderly.",[377,378,379,380,218,30,381],"Hypoxia","Cerebral Hypoxia","Brain Diseases","Exercise","Healthy Aging","2026-05-04",{"date":384,"type":41},"2026-05-08",{"date":386,"type":41},"2021-10-13",{"date":388,"type":23},"2026-09",{"name":390,"class":48},"University Hospital, Grenoble",{"id":392,"slug":393,"hasResults":12,"nctId":394,"briefTitle":395,"officialTitle":395,"acronym":4,"eligibilityCriteria":396,"healthyVolunteers":12,"sex":294,"minAge":268,"maxAge":4,"enrollmentInfo":397,"targetDuration":4,"studyType":24,"phases":399,"briefSummary":401,"conditions":402,"keywords":408,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":414,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":420,"locationsCount":49},"100572016","phase-2-memantine-and-exercise-to-improve-cognitive-function-and-modulate-biological-pathways-of-cognitive-decline-during-chemotherapy-in-breast-cancer-100572016","NCT06727773","Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer","Inclusion Criteria:\n\nIn order to participate in the study a subject must meet all of the eligibility criteria outlined below.\n\n* Female\n* Age ≥ 18 years at the time of consent.\n* Stage I-III Breast Cancer\n* Recommended chemotherapy\n* Enroll prior to 3rd cycle of chemotherapy\n* English-speaking\n\nExclusion Criteria:\n\n* Allergy to memantine\n* Previous chemotherapy (prior to the current regimen),\n* Severe cognitive impairment, defined by Blessed Orientation Memory Concentration Test Score ≥11\n* Myocardial infarction in the last 6 months\n* Cardiovascular or orthopedic limitations to exercise\n* Severe mental illness (i.e., schizophrenia or bipolar affective disorder)\n* Current alcohol or drug abuse\n* Inability to swallow capsules \\\u003C\u002F= 5mL\u002Fmin\n* CrCl \\\u003C\u002F= 5mL\u002Fmin",{"count":398,"type":23},90,[400],"PHASE2","This randomized, placebo-controlled trial aims to assess the feasibility, acceptability, and preliminary efficacy of memantine and the University of Carolina (UNC)'s Get Real \\& Heel cancer exercise program (MEM+EX) in addressing cancer-related cognitive impairment (CRCI) and underlying CRCI biomarkers. Ninety stage I-III breast cancer patients during chemotherapy will be randomized into three groups: MEM+EX, memantine, or placebo. The study will evaluate recruitment, retention, adherence, acceptability, cognitive function, brain-derived neurotrophic factor (BDNF), inflammatory markers, and frailty at multiple time points.",[403,404,29,30,348,405,406,407],"Breast Cancer","Locally Advanced Breast Cancer","Breast Cancer Stage I","Breast Cancer Stage II","Breast Cancer Stage III",[409,410,411,412,413],"chemotherapy","memantine","placebo-controlled","exercise","Get Real & Heel cancer exercise program",{"date":415,"type":41},"2026-05-06",{"date":417,"type":41},"2025-08-19",{"date":419,"type":23},"2029-06-15",{"name":421,"class":48},"UNC Lineberger Comprehensive Cancer Center",{"id":423,"slug":424,"hasResults":12,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":428,"eligibilityCriteria":429,"healthyVolunteers":17,"sex":18,"minAge":98,"maxAge":4,"enrollmentInfo":430,"targetDuration":4,"studyType":24,"phases":432,"briefSummary":433,"conditions":434,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":437,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":443,"locationsCount":49},"100506654","a-smart-trial-of-adaptive-exercises-to-optimize-aerobic-fitness-responses-100506654","NCT05877196","A SMART Trial of Adaptive Exercises to Optimize Aerobic-Fitness Responses","Precision Medicine in Alzheimer's Disease: A SMART Trial of Adaptive Exercises and Their Mechanisms of Action Using AT(N) Biomarkers to Optimize Aerobic-Fitness Responses (The FIT-AD SMART Trial)","SMART","Inclusion Criteria:\n\nParticipants:\n\n* Clinical diagnosis of MCI or probable and possible mild AD dementia according to 2011 Alzheimer's association-NIA criteria.\n* Community-dwelling, e.g., homes and assisted living\n* Age 65 years and older\n* Medical clearance from PCP or cardiovascular provider\n* Have a qualified study partner\n* Agree to the blood draws\n* Verified MRI safety\n\nStudy Partner:\n\n* Age 18 or older\n* Contact with participant ≥ 2 times per week for ≥ 6 months\n* Know the participant's memory status and ability to perform activities of daily living\n* Consent to participant\n\nExclusion Criteria:\n\nParticipants\n\n* Resting HR ≤ 50 or ≥ 100 beats\u002Fmin after 5-minutes of quiet resting\n* American College of Sports Medicine contraindications to exercise\n* New, unevaluated symptoms or diseases a healthcare provider has not evaluated\n* Abnormal cardiac condition uncovered during VO2peak testing\n* Enrollment in another intervention that aims at improving cognition\n* Moderate to strenuous exercise ≥150 minutes a week in the previous 6 months\n* ≥ 2 anti-depression medications, or poorly managed or unstable depression\n* Poorly managed or unstable anxiety\n\nStudy partners:\n\n* none",{"count":431,"type":23},216,[26],"The goal of this clinical trial is to test 6 months of aerobic exercise in older adults who are 65 years or older and have mild cognitive impairment (MCI) or probable\u002Fpossible mild Alzheimer's Disease. The main questions it aims to answer are:\n\n* test the effects of aerobic exercise on aerobic fitness, white matter hyperintensity (WMH) volume, and patient-centered outcomes;\n* identify the best exercise to improve aerobic fitness and reduce non-responses over 6 months; and\n* examines the mechanisms of aerobic exercise's action on memory in older adults with early AD.\n\nParticipants will receive 6 months of supervised exercise, undergo cognitive data collection and exercise testing 5 times over a year span, have an MRI brain scan 3 times over a one-year span, and have monthly follow-up discussions on health and wellness.",[66,65,29,30,435,436],"Memory Loss","Memory Impairment",{"date":438,"type":41},"2026-05-05",{"date":440,"type":41},"2023-06-22",{"date":442,"type":23},"2028-06-30",{"name":444,"class":48},"Arizona State University",{"id":446,"slug":447,"hasResults":12,"nctId":448,"briefTitle":449,"officialTitle":450,"acronym":451,"eligibilityCriteria":452,"healthyVolunteers":12,"sex":18,"minAge":98,"maxAge":453,"enrollmentInfo":454,"targetDuration":4,"studyType":24,"phases":456,"briefSummary":457,"conditions":458,"keywords":462,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":469,"startDateStruct":470,"completionDateStruct":472,"leadSponsor":474,"locationsCount":49},"100484793","in-dementia-clinical-trials-100484793","NCT05592678","δ in Dementia Clinical Trials","Novel Methods for Clinical Trials in Dementia and Cognitive Decline","δND","Inclusion Criteria:\n\n1. Ambulatory outpatient volunteers with co-informants.\n2. Aged 65-100 years\n3. Clinical diagnosis of AD, or MCI.\n4. Capacity to give informed consent.\n5. GDS score (15 item) ≤ 8.\n6. No significant visual or hearing impairments\n7. Standardized dECog score between 1.0 and 5.0 relative to ADNI's cohort.\n\nExclusion Criteria:\n\n1. A history of psychosis, including visual hallucinations;\n2. History or treatment for Parkinson's, or tremor, or Rapid Eye Movement (REM) behavior disorder;\n3. History of bradycardia or syncopal events;\n4. Treatment for cancer in the last 5 years (excluding skin cancers);\n5. Major surgery in the last year;\n6. Treatment for a seizure disorder with anticonvulsants;\n7. Treatment for agitation or psychosis with neuroleptics (treatment of anxiety or insomnia allowed);\n8. Current treatment with donepezil or any other AChEI or exposure within the last six months\n9. With a recently started Donepezil Rx (\\\u003C 2 weeks), inability to stop Donepezil treatment for 14 days prior to study enrollment.\n10. AChEI treatment not appropriate due to negative risk\u002Fbenefit ratio based on medical Hx and symptoms during screening. Evaluated by PI and referring clinician.\n11. Co-participation in another study that the PI feels would pose a safety risk or adversely affect data integrity of this study.","100 Years",{"count":455,"type":23},200,[26],"The goal of this clinical trial is to demonstrate potential improvements in clinical trial methods relating to dementia and cognitive decline. The main questions it aims to answer are:\n\n* Can an intervention's outcome be better assessed by a latent variable (\"δ\") integrating cognitive performance with functional status?\n* Can latent biomarkers of δ guide the selection of an intervention that will modulate dementia severity?\n* Can a latent variable, derived from information collected remotely from caregivers, preselect subjects most likely to respond to the intervention?\n* Is the effect of the intervention in fact medicated by changes in the targeted biomarker?\n\nIn this case, the biomarker will be a latent variable derived from several proteins measured in blood (i.e., so-called \"adipokines\"). The intervention will be donepezil, a medication approved for the treatment of Alzheimer's Disease, but only recently associated with adipokine changes.\n\nParticipants with cognitive impairment and their caregivers will be interviewed by telephone and those newly prescribed donepezil by their provider for cognitive impairment will be recruited and enrolled. On the basis of the caregiver's report, the cognitively impaired subjects will be assigned to two groups based on a prediction of their response to donepezil. Researchers will compare those groups to see if dementia severity, as measured by δ, improves in predicted responders, and whether the change in the d-score is mediated by changes in adipokines.",[459,460,30,461],"Alzheimer's Disease (AD)","Dementia","Mild Cognitivie Impairment (MCI)",[463,464,465,466,467],"adipokines","cognition","dementia","functional status","intelligence","2026-04-30",{"date":438,"type":41},{"date":471,"type":41},"2024-08-05",{"date":473,"type":23},"2028-11-30",{"name":475,"class":48},"The University of Texas Health Science Center at San Antonio",{"id":477,"slug":478,"hasResults":12,"nctId":479,"briefTitle":480,"officialTitle":481,"acronym":4,"eligibilityCriteria":482,"healthyVolunteers":12,"sex":18,"minAge":163,"maxAge":4,"enrollmentInfo":483,"targetDuration":4,"studyType":24,"phases":484,"briefSummary":485,"conditions":486,"keywords":488,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":495,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":500,"locationsCount":502},"100516315","mindwalk-intervention-for-older-south-asian-caregivers-of-people-with-cognitive-disabilities-cd-100516315","NCT06002919","MindWalk Intervention for Older South Asian Caregivers of People With Cognitive Disabilities (CD)","MindWalk: A Mindful Walking Intervention for Older South Asian Family Caregivers of People With Cognitive Disabilities (CD) With Perceived Psychological Stress","Inclusion Criteria:\n\n* Older South Asian family caregivers (45 years or older) caring for a person with cognitive disability of any age\n* Self-reported insufficient physical activity (defined as participating in moderate physical activity less than 60 min\u002Fweek) and not engaged in mindfulness training\n* Self-reporting of experiencing psychological stress;\n* Own a smartphone with a data plan or Bluetooth-enabled device (e.g., tablets such as iPad) to sync data from the Fitbit tracker to the Fitbit app and to receive text messages\n* Ability to speak, understand, read and write English; ability to provide informed consent\n\nExclusion Criteria:\n\n* Non-South Asian caregivers\n* Caregivers less than 45 years old\n* Having self-reported sufficient physical activity (defined as participating in moderate physical activity more than 60 min\u002Fweek) and engaged in some form of mindfulness training\n* Not owning a smartphone with a data plan or Bluetooth-enabled device (e.g., tablets such as iPad)\n* Mobility limitation\n* Taking medications or other behavioral treatment for stress reduction; acute or chronic diseases at baseline\n* Inability to understand, speak, read, and write English\n* Inability to provide informed consent",{"count":271,"type":23},[26],"Older South Asian family caregivers experience elevated psychological stress and limited physical activity (PA) due to caregiving responsibilities and additional factors such as lack of access to services, cultural\u002Flinguistic barriers, stigma and discrimination. South Asian family caregivers are especially underserved and are a growing ethnic group in the US. Both PA and cognitive training (CT) have shown to improve cognitive function in older adults who experience cognitive function decline because of psychological stress. However, there are no studies using this approach for this population. We propose a randomized control trial pilot study to address this gap. Driven by a Community Advisory Committee (CAC) we will develop this 12-week mindful walking intervention using a participatory methodology in partnership with UIC's Cognition Behavior and Mindfulness Clinic that combines the PA of walking and the CT through mindfulness. We will recruit fifty participants and will randomly and equally assign 25 people to the intervention and 25 people to the control group. The intervention will include: 1) a mindful walking training followed by 2) a prescribed mindful walking regimen, 3) self-reporting of adherence to regimen by the participants using activity logbooks and use of a user-friendly PA tracker (Fitbit) for daily step count, and 4) personalized text messages with reminders and motivational messages for participants to do the mindful walking as prescribed including a weekly check-in call or text message for accountability. The primary aim of the proposed pilot study is to evaluate the feasibility and acceptability of the protocol and intervention implementation. A secondary aim will evaluate the intervention to examine preliminary efficacy in reduction of psychological stress, improvement in cognitive function, increase in physical activity, and increased self-efficacy (self-efficacy for coping with stress, self-efficacy for physical activity, and overall self-efficacy). The findings of this pilot project will provide evidence-based data to support a larger scale study proposal for future funding such as the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR) field initiative award, or the National Institute of Health (NIH) Research Project Grant (R21 NIH Exploratory\u002FDevelopmental Research Grant Award) award, especially National Institute on Aging (NIA) grants.",[487,30],"Stress, Psychological",[489,490,491,492,108,493],"Caregiver of a person with cognitive disability","Perceived psychological stress","Cognitive Function","Mindful Walking","Self-efficacy","2026-04-27",{"date":329,"type":41},{"date":497,"type":41},"2023-10-31",{"date":499,"type":23},"2026-12-31",{"name":501,"class":48},"University of Illinois at Chicago",8,{"id":504,"slug":505,"hasResults":12,"nctId":506,"briefTitle":507,"officialTitle":508,"acronym":4,"eligibilityCriteria":509,"healthyVolunteers":12,"sex":18,"minAge":188,"maxAge":510,"enrollmentInfo":511,"targetDuration":4,"studyType":24,"phases":513,"briefSummary":514,"conditions":515,"keywords":516,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":520,"lastUpdatePostDateStruct":521,"startDateStruct":523,"completionDateStruct":524,"leadSponsor":526,"locationsCount":49},"100635025","effects-of-accelerated-rtms-on-cognitive-function-100635025","NCT07547319","Effects of Accelerated rTMS on Cognitive Function","Clinical and Neurophysiological Effects of Accelerated rTMS on Cognitive Function: A Prospective Pilot Study","Inclusion Criteria:\n\nEach potential subject must satisfy all of the following criteria to be enrolled in the study:\n\n* Subject must be 50 to 90 years of age, inclusive, on the day of signing informed consent.\n* Documented cognitive function decline, defined as:\n\nMoCA score of 10 to 25, inclusive (indicating mild to moderate cognitive impairment), OR Clinical diagnosis of mild cognitive impairment (MCI) or mild dementia based on established DSM-5 diagnostic criteria.\n\n* Ability to provide written informed consent, or availability of a legally authorized representative to provide consent.\n* Subject must sign an ICF indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study.\n* Sufficient visual and auditory acuity to complete cognitive assessments.\n* Stable doses of any cognitive-enhancing medications (e.g., cholinesterase inhibitors, memantine) for at least 4 weeks prior to screening, with no anticipated changes during the study period.\n* Availability and willingness to complete all scheduled study visits.\n* Presence of a reliable study partner or caregiver who can provide information about the participant's cognitive and functional status.\n* Ability to determine the motor threshold of the participant. The participant's motor threshold could be established as the minimum stimulus required to induce contraction of the right thumb.\n* Subjects willing and able to abstain from partaking in any treatments other than the study procedure for the improvement in cognitive function, including non-invasive brain stimulation treatments other than the study procedure during study participation.\n* Subjects willing and able to maintain their regular (pre-procedure) diet and exercise regimen without affecting significant change in either direction during study participation.\n* Willingness to comply with study instructions and to return to the clinic for the required visits.\n* Women of child-bearing potential are required to use birth control measures during the whole duration of the study.\n\nExclusion Criteria:\n\nAny potential subject who meets any of the following criteria will be excluded from participating in the study:\n\n* Electronic implants in or near the head - rTMS devices are contraindicated for use in patients who have active or inactive implants in or near the head including device leads, deep brain stimulators, cochlear implants, ocular implants, and vagus nerve stimulators, implanted devices such as cardiac pacemakers, defibrillators, and neurostimulators.\n* Metallic, ferromagnetic, or other magnetic-sensitive implants\u002Fobjects in or near the head - rTMS devices are contraindicated for use in patients who have conductive, ferromagnetic, or other magnetic-sensitive metals implanted in their head (with some exceptions in the mouth - see Operator's Manual) or within 12 inches (30 cm) of the therapy coil. Examples include implanted electrodes\u002Fstimulators, aneurysm clips or coils, stents, bullet fragments, jewelry, hair barrettes, and tattoos with metallic ink.\n* Drug pumps within 12 inches (30 cm) of the therapy coil.\n* Inability to determine the motor threshold of the participant (i.e., the minimum stimulus required to induce contraction of the right thumb cannot be established).\n* History of seizure disorder or epilepsy, except for a single remote seizure more than 5 years ago, which may be permitted at investigator discretion.\n* Elevated risk of seizure due to traumatic brain injury with loss of consciousness \\>30 minutes within the past 12 months.\n* Current use of medications known to significantly lower seizure threshold (e.g., clozapine, bupropion at doses \\>450 mg\u002Fday, theophylline, high-dose tricyclic antidepressants) or recent dose reduction of anticonvulsant medications or benzodiazepines within 4 weeks of screening.\n* Severe dementia, defined as MoCA score below 10, or inability to follow simple verbal commands or complete basic cognitive assessments.\n* Rapidly progressive dementia (e.g., suspected prion disease, autoimmune encephalitis).\n* Brain tumor, intracranial hemorrhage within the past 12 months, arteriovenous malformation, or increased intracranial pressure.\n* Acute stroke within the past 3 months (stable chronic stroke with cognitive sequelae may be included at investigator discretion).\n* Has a current diagnosis of psychotic disorder, bipolar disorder, or other psychiatric condition that, in the investigator's opinion, would interfere with the subject's ability to participate in the trial.\n* Has a current or recent history of serious suicidal ideation within the past 6 months, corresponding to a positive response on item 4 (active suicidal ideation with some intent to act, without specific plan) or item 5 (active suicidal ideation with specific plan and intent) on the C-SSRS, or a history of suicidal behavior within the past year, as validated by the C-SSRS at screening.\n* History of substance or alcohol use disorder of moderate to severe severity according to DSM-5 criteria within 6 months before screening, or positive test result(s) for drugs of abuse (including opiates, cocaine, cannabinoids, methamphetamines, amphetamines) at screening.\n* Has history of or current clinically significant and\u002For unstable medical condition that could interfere with study participation or pose safety concerns, including but not limited to:\n\nModerate or severe hepatic impairment (Child-Pugh Score ≥7) Severe renal impairment (estimated creatinine clearance below 30 mL\u002Fmin or serum creatinine \\>2 mg\u002FdL) Unstable cardiac, vascular, or pulmonary disease Note: Subjects with chronic but stable, well-controlled conditions may be allowed in the study upon agreement with the investigator.\n\n* Has uncontrolled hypertension (systolic blood pressure \\>160 mm Hg or diastolic blood pressure \\>100 mm Hg, despite diet, exercise, or a stable dose of antihypertensive therapy) at screening. A subject with hypertension may be included if the subject's hypertension has been controlled for at least 3 months prior to screening, and the dosage of any antihypertensive medication has been stable for the past 3 months.\n* Has clinically significant ECG abnormalities at screening, defined as:\n\nQTc interval (Fridericia's formula): ≥450 msec (males); ≥470 msec (females) Evidence of 2nd or 3rd degree atrioventricular block, or 1st degree atrioventricular block with PR interval \\>210 msec Left bundle branch block Features of new ischemia Other clinically important arrhythmia Note: Subjects with right bundle branch block may be allowed provided confirmation that right bundle branch block is not associated with underlying cardiac\u002Flung diseases.\n\n\\- Has a known malignancy or history of malignancy within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy that, in the opinion of the investigator, is considered cured with minimal risk of recurrence).\n\nHad clinically significant acute illness within 7 days prior to study rTMS treatment.\n\n\\- Had major surgery (e.g., requiring general anesthesia) within 2 weeks before screening, or will not have fully recovered from surgery, or has surgery planned during the time the subject is expected to participate in the study.\n\nNote: Subjects with planned surgical procedures to be conducted under local anesthesia may participate.\n\n* Is pregnant or breastfeeding while enrolled in this study or within 1 month after the last session of study rTMS treatment.\n* Has received an investigational drug or used an invasive investigational medical device within 3 months before screening, or is currently enrolled in an investigational study.\n* Prior treatment with rTMS within 6 months of screening.\n* Subjects willing to partake in any treatments other than the study procedure for the improvement in cognitive function, including non-invasive brain stimulation treatments other than the study procedure, during study participation.\n* Has psychological and\u002For emotional problems which would render the informed consent invalid, or limit the ability of the subject to comply with the study requirements.\n* Has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.\n* Is an employee of the investigator or study site, with direct involvement in the proposed study or other studies under the direction of that investigator or study site, as well as family members of the employees or the investigator.\n\nNOTE: Investigators should ensure that all study enrollment criteria have been met at screening. If a subject's clinical status changes after screening but before the first rTMS treatment session such that he or she no longer meets all eligibility criteria, then the subject should be excluded from participation in the study.","90 Years",{"count":512,"type":23},80,[26],"Cognitive impairment, including mild cognitive impairment (MCI) and mild dementia, is a growing public health challenge with limited effective treatment options. Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technique that has shown promise for improving cognitive function, but most studies have used conventional protocols and relied on global screening tools that may not capture domain-specific changes.\n\nThe purpose of this study is to evaluate the efficacy and tolerability of repetitive transcranial magnetic stimulation (rTMS) delivered via the EXOMIND™ device (BTL-699-2) for improving cognitive function in adults aged 50 to 90 years with mild to moderate cognitive impairment. The study asks whether a course of 6 rTMS sessions targeting the left dorsolateral prefrontal cortex, administered twice weekly over approximately 3 weeks, can produce meaningful and sustained improvements in global and domain-specific cognitive function over a 3-month follow-up period.\n\nThis is a single-center, open-label, prospective pilot study enrolling 80 participants with documented cognitive decline (Montreal Cognitive Assessment \\[MoCA\\] score 10-25). Participants will receive 6 sessions of high frequency rTMS (6,300 pulses per session at alternating frequencies of 12, 15, and 18 Hz) over approximately 3 weeks. The primary outcome is the change from baseline in MoCA score at 1-month follow-up. Secondary outcomes include changes in MoCA score at post-treatment and 3-month follow-up, changes in domain-specific cognitive measures (visual spatial working memory, episodic memory, deductive reasoning, mental rotation, verbal short term memory, and attention) assessed by the Creyos cognitive battery, and changes in depressive symptoms measured by the Patient Health Questionnaire-9 (PHQ-9). Assessments are performed at baseline, post treatment, 1-month follow-up, and 3-month follow-up. Total study duration per participant is up to 139 days.",[30,29],[517,518,30,519],"rTMS","ExoMind","MCI","2026-04-20",{"date":522,"type":41},"2026-04-23",{"date":329,"type":23},{"date":525,"type":23},"2027-12-31",{"name":527,"class":48},"San Francisco Neurology and Sleep Center",{"id":529,"slug":530,"hasResults":12,"nctId":531,"briefTitle":532,"officialTitle":532,"acronym":533,"eligibilityCriteria":534,"healthyVolunteers":17,"sex":18,"minAge":268,"maxAge":535,"enrollmentInfo":536,"targetDuration":4,"studyType":24,"phases":538,"briefSummary":539,"conditions":540,"keywords":544,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":552,"lastUpdatePostDateStruct":553,"startDateStruct":555,"completionDateStruct":556,"leadSponsor":558,"locationsCount":49},"100589103","amplifi-adaptive-modulation-of-plasticity-through-lactate-and-fitness-interventions-100589103","NCT06950060","AMPLIFI: Adaptive Modulation of Plasticity Through Lactate and Fitness Interventions","AMPLIFI","Inclusion Criteria:\n\nFor All Participants:\n\n* Able to provide informed consent\n* Right-handed (for TMS consistency)\n* English-speaking\n* Clearance for moderate-intensity aerobic exercise\n* Able to safely sit and pedal a stationary cycle ergometer\n* No contraindications to TMS (e.g., no metal in skull, pacemakers, or seizure history)\n\nYounger Adults (18-35):\n\n* No history of neurological or psychiatric conditions\n* Not currently on medications that affect the central nervous system\n\nOlder Adults (60-85):\n\n* No diagnosis of dementia\n* Independent in activities of daily living\n* No stroke history\n\nStroke Survivors (40-85):\n\n* At least 6 months post-stroke (chronic phase)\n* Medically stable and cleared for aerobic exercise\n* Able to engage in motor learning task (with or without hemiparetic adaptations)\n\nExclusion Criteria:\n\n* History of epilepsy or seizures\n* Current substance abuse or uncontrolled psychiatric disorder\n* Severe cardiovascular disease or unstable medical condition\n* Pregnancy\n* Contraindications to TMS or exercise testing (e.g., implanted neurostimulators, severe hypertension)\n* Participation in another interventional trial within the past 30 days","85 Years",{"count":537,"type":23},48,[26],"The AMPLIFI study (Adaptive Modulation of Plasticity through Lactate and Fitness Interventions) investigates how short-term aerobic exercise influences brain plasticity and learning in older adults and stroke survivors. The study compares three groups: one performing aerobic cycling at an intensity that elevates lactate levels, one performing low-intensity exercise, and one receiving health education without exercise.\n\nAll participants will complete motor learning tasks and undergo brain-stimulation testing using transcranial magnetic stimulation (TMS) to assess how well the brain responds to training. The goal is to understand whether different types of exercise can improve brain function, movement, and memory, and how the body's response to exercise (like lactate levels) might support brain health.\n\nThis research may help identify low-cost, non-invasive interventions-such as targeted exercise-that improve motor and cognitive outcomes in aging and stroke recovery.",[541,218,30,542,543],"Stroke, Chronic","Motor Dysfunction","Neuroplasticity",[545,546,543,547,548,218,549,550,551],"Transcranial Magnetic Stimulation (TMS)","Cortical Inhibition","Aerobic Exercise","Motor Learning","Stroke Rehabilitation","Cortical Excitability","GABAergic Inhibition","2026-04-16",{"date":554,"type":41},"2026-04-17",{"date":358,"type":23},{"date":557,"type":23},"2030-01-01",{"name":559,"class":48},"University of Alabama at Birmingham",{"id":561,"slug":562,"hasResults":12,"nctId":563,"briefTitle":564,"officialTitle":565,"acronym":566,"eligibilityCriteria":567,"healthyVolunteers":12,"sex":18,"minAge":58,"maxAge":568,"enrollmentInfo":569,"targetDuration":4,"studyType":24,"phases":571,"briefSummary":572,"conditions":573,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":552,"lastUpdatePostDateStruct":574,"startDateStruct":576,"completionDateStruct":578,"leadSponsor":579,"locationsCount":49},"100533273","essential-fats-for-enhancing-cognitive-thinking-effect-study-100533273","NCT06223672","Essential Fats For Enhancing Cognitive Thinking (EFFECT) Study","Essential Fats For Enhancing Cognitive Thinking (EFFECT) Study: Dietary Fat Quality and Cognitive Impairment","EFFECT","Inclusion Criteria:\n\n* Subjective cognitive impairment\n* BMI ≥30 kg\u002Fm2\n* HbA1C \\\u003C6.5%\n\nExclusion Criteria:\n\n* Diagnosis og cognitive impairment or dementia\n* Montreal Cognitive Assessment (MoCA) score of \\\u003C26\n* Current or previous diagnosis of Diabetes or use of diabetes medications\n* Current diagnosis of or current treatment of cancer other than non-melanoma skin cancer\n* Gastrointestinal diseases or disorders (including pancreatic and gastric bypass surgery) where consumption of the study foods would be contraindication or where the disease or disorder could negatively affect nutrient absorption and\u002For would prevent participants from tolerating the study foods\n* Hyperthyroidism diagnosis\n* Food Allergy or intolerances\n* Any dietary restriction where consumption of the study foods, study meals\u002Fsnack or meal challenge or any ingredient would be contraindicated\n* Use of some oil supplements in the past 4 weeks prior to enrolling\n* Pregnancy and lactation\n* Inability to access veins for venipuncture\n* Antibiotic use in the past month\n* Psychostimulant or nootropic medication use\n* Current use of supplements or medications for weight loss or following a weight loss program\n* Severe or uncontrolled autoimmune diseases\n* Current or previous diagnosis of severe kidney failure, liver cirrhosis and some pulmonary diseases\n* Heart disease events (including stroke or heart attack) within last 3 months prior to enrollment\n* Alcohol or drug abuse","75 Years",{"count":570,"type":23},88,[26],"The proposed research is a randomized crossover trial designed to assess changes in postprandial cognitive function and the gut-brain axis in adults with subjective cognitive complaints who consume 1 study snack per day for 1 week.",[30,29],{"date":575,"type":41},"2026-04-21",{"date":577,"type":41},"2024-02-07",{"date":499,"type":23},{"name":286,"class":48},{"id":581,"slug":582,"hasResults":12,"nctId":583,"briefTitle":584,"officialTitle":585,"acronym":4,"eligibilityCriteria":586,"healthyVolunteers":17,"sex":18,"minAge":98,"maxAge":4,"enrollmentInfo":587,"targetDuration":4,"studyType":24,"phases":589,"briefSummary":590,"conditions":591,"keywords":594,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":598,"lastUpdatePostDateStruct":599,"startDateStruct":601,"completionDateStruct":603,"leadSponsor":604,"locationsCount":49},"100511115","mpath-for-low-income-older-adults-100511115","NCT05935241","mPATH for Low-income Older Adults","mHealth-Facilitated Physical Activity Toward Health (mPATH) Intervention for Low-Income Older Adults","Inclusion Criteria:\n\n* self-reported difficulty of sleep\n* lack of physical activity\u002Fexercise\n* low household income\n* capacity for moderate intensity exercise\n\nExclusion Criteria:\n\n* untreated sleep apnea\n* severe depression or anxiety\n* dementia\n* history of neurologic or psychiatric disorders, neurodevelopmental impairment, traumatic brain injury\n* current enrollment in another clinical trial",{"count":588,"type":23},176,[26],"Although empirical research suggests that physical activity interventions benefit cognition and sleep in older adults in general, the possible benefit of physical activity is understudied in low-income older adults. The study aims to test the immediate and sustaining efficacy of an mHealth-facilitated Physical Activity Toward Health (mPATH) intervention on cognitive function and sleep in low-income older adults.",[592,593,30],"Sedentary Time","Insomnia",[595,596,597],"physical activity","memory","sleep","2026-04-09",{"date":600,"type":41},"2026-04-13",{"date":602,"type":41},"2024-05-30",{"date":203,"type":23},{"name":605,"class":48},"Johns Hopkins University",{"id":607,"slug":608,"hasResults":12,"nctId":609,"briefTitle":610,"officialTitle":611,"acronym":612,"eligibilityCriteria":613,"healthyVolunteers":17,"sex":18,"minAge":58,"maxAge":4,"enrollmentInfo":614,"targetDuration":4,"studyType":215,"phases":4,"briefSummary":616,"conditions":617,"keywords":620,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":624,"lastUpdatePostDateStruct":625,"startDateStruct":627,"completionDateStruct":629,"leadSponsor":630,"locationsCount":49},"100604580","plant-based-diets-and-healthy-aging-100604580","NCT07151365","Plant-based Diets and Healthy Aging","Plant-based Diets and Healthy Aging - the Tzu Chi Aging Study (TCAS)","TCAS","Inclusion Criteria:\n\n* Age 40 years or older.\n* Volunteers of the Tzu Chi Foundation.\n* Participating in the 2-day comprehensive health examination program.\n\nExclusion Criteria:\n\n* Pregnant individual.\n* Diagnosed with dementia or poor cognition resulting in inability to answer questionnaires.",{"count":615,"type":23},5000,"This prospective study investigates the health effects of vegetarian and plant-based diets in middle-aged and older adults in Taiwan, specifically, recruiting 5000 Tzu Chi volunteers. Previous Tzu Chi cohorts found vegetarian diets were protectively associated with incidences of diabetes, stroke, gout, cataracts, insomnia, and gallstones, while reducing healthcare costs. The study also aims to clarify dietary patterns-particularly plant-based and vegetarian diets-and determine how potential deficiencies or excesses of various nutrients influence common aging-related health issues, including healthy cognitive decline, sarcopenia, and the risk of age-related diseases, in order to inform dietary and lifestyle recommendations that promote healthy aging and maintain physical function.",[381,618,619,30],"Sarcopenia","Frailty",[621,622,623,112,618,619],"Vegetarian diets","Plant-based diets","Healthy aging","2026-04-06",{"date":626,"type":41},"2026-04-08",{"date":628,"type":41},"2025-09-01",{"date":284,"type":23},{"name":631,"class":48},"National Health Research Institutes, Taiwan",{"id":633,"slug":634,"hasResults":12,"nctId":635,"briefTitle":636,"officialTitle":637,"acronym":4,"eligibilityCriteria":638,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":535,"enrollmentInfo":639,"targetDuration":4,"studyType":24,"phases":641,"briefSummary":642,"conditions":643,"keywords":647,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":660,"lastUpdatePostDateStruct":661,"startDateStruct":663,"completionDateStruct":665,"leadSponsor":667,"locationsCount":49},"100567542","effects-of-real-vs-soundless-acoustic-stimulation-during-deep-sleep-on-brain-activity-memory-and-blood-biomarkers-in-older-adults-60-85-with-mild-memory-impairment-100567542","NCT06669546","Effects of Real vs. Soundless Acoustic Stimulation During Deep Sleep on Brain Activity, Memory, and Blood Biomarkers in Older Adults (60-85) With Mild Memory Impairment","Preventing Cognitive Decline Using Portable, Non-invasive Sleep Enhancement","Inclusion Criteria:\n\n* Written informed consent\n* Age between 60 and 85 years\n* Cognitive impairment (subjective and\u002For MoCA between 23-26)\n* Native German speakers or comparably fluent\n* Normal or corrected-to-normal vision.\n* Intact hearing\n* A close cohabitant (partner\u002Fsibling) should be present to support participants in using study materials\u002Fdevices.\n\nExclusion Criteria:\n\n* Insomnia assessed by the Regensburg Insomnia Scale (RIS; Crönlein et al., 2013)\n* Restless leg syndrome assessed by questions concerning typical symptoms.\n* Sleep apnoea assessed by the Berlin Questionnaire (BQ; Netzer et al., 1999)\n* Severely irregular sleep patterns assessed by the RIS and the Pittsburgh sleep quality index (PSQI; Buysse et al., 1989)\n* Symptoms of depression (Geriatric Depression Scale (GDS; Yesavage et al., 1982) ≥ 5)\n* History of untreated severe neurological and psychiatric diseases\n* Alcohol or substance abuse\n* Use of medication acting on the central nervous system",{"count":640,"type":23},60,[26],"This study aims to explore a non-invasive way to improve memory and slow cognitive decline in older adults by enhancing sleep quality. Dementia, a leading cause of death worldwide, is often associated with disturbed sleep, particularly the loss of deep, slow-wave sleep (SWS). SWS is important for memory and clearing waste from the brain. Poor SWS can worsen memory loss and allow harmful waste to build up, which may increase the risk of dementia.\n\nThe investigators are testing whether phase-locked auditory stimulation (PLAS) can improve SWS in people at a mild stage of cognitive impairment. PLAS uses short sounds played at specific moments to strengthen slow-wave brain activity during sleep. The investigators previous laboratory based research has shown that this can improve memory and help with clearing waste from the brain. Now, the investigators want to test this in a real-world setting, over a longer period, which is unfeasible in a laboratory setting.\n\nIn this study, 60 older adults will use home-use devices that deliver either real or sham (soundless) PLAS across two different 4-week periods. Memory will be tested using engaging \"serious games.\" Before and after each experimental period, blood samples will be taken to measure dementia-related markers, and cognitive batteries will be performed. The investigators expect that PLAS will improve sleep, and that this will have a downstream effect on memory and brain clearance, potentially slowing the process of cognitive decline.\n\nIf successful, this could lead to the development of an affordable treatment that helps people maintain brain health and prevent dementia.",[30,65,644,645,646],"Subjective Cognitive Decline (SCD)","Mild Cognitive Impairment (MCI)","Cognitive Impairment, Mild",[648,460,649,650,651,652,653,654,74,655,656,657,658,659],"Sleep","Prevention","Phase-locked auditory stimulation","Blood-based biomarkers","Home","Longitudinal","Electroneurophysiology","Memory","Cognition","Serious games","Old age","Human","2026-04-02",{"date":662,"type":41},"2026-04-03",{"date":664,"type":41},"2025-02-21",{"date":666,"type":23},"2028-12",{"name":668,"class":48},"University of Bern",{"id":670,"slug":671,"hasResults":12,"nctId":672,"briefTitle":673,"officialTitle":673,"acronym":4,"eligibilityCriteria":674,"healthyVolunteers":17,"sex":18,"minAge":188,"maxAge":453,"enrollmentInfo":675,"targetDuration":4,"studyType":24,"phases":677,"briefSummary":678,"conditions":679,"keywords":680,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":684,"lastUpdatePostDateStruct":685,"startDateStruct":687,"completionDateStruct":689,"leadSponsor":691,"locationsCount":49},"100617047","feasibility-of-a-smartphone-application-intervention-in-community-settings-a-pretest-posttest-pilot-study-100617047","NCT07313540","Feasibility of A Smartphone Application Intervention in Community Settings: A Pretest-Posttest Pilot Study","Inclusion Criteria:\n\n1. Individuals aged 50+ who has a primary source of assistance (no age limitation for the caregiver)\n2. Both care recipient and caregiver can participate in the study for six weeks in total,\n3. Both care recipient and caregiver can read, listen, write, and speak English\n4. Both care recipient and caregiver have a personal smartphone.\n\nExclusion Criteria:\n\n1. People who are diagnosed with any middle to severe cognitive symptoms (dementia or Alzheimer's Disease) or any psychiatric disease (depression, bipolar, PTSD, Schizophrenia, anxiety disorders, eating disorders)\n2. People who are at hospice care\n3. People who plan to move out of the current area in one year, and (4) people younger than 50 (but no age limitation for caregivers)",{"count":676,"type":23},40,[26],"The objective of this project is to test the feasibility of using a smartphone app in a community setting through collaborating with community-based organizations. The app is called utmbHealthyBrain and it has three activities: (1) drawing, (2) Tai-Chi and meditation, and (3) prayer reading. It also has a \"share\" function to enable users to interact with their family and friend. These activities can be translated to humans' well-beings such as a more stable emotion, more muscle movement, and better social engagement. This app does not collect any personal data and users are not required to register an account either. The overall study period is 6 weeks including one introduction session (week 1), four weeks of intervention (week 2 to 5), and final feedback session (week 6).",[218,460,30],[681,682,683],"Smarthphone","Tai-Chi","Meditation","2026-03-25",{"date":686,"type":41},"2026-03-27",{"date":688,"type":23},"2026-10",{"date":690,"type":23},"2027-10",{"name":692,"class":48},"The University of Texas Medical Branch, Galveston",{"id":694,"slug":695,"hasResults":12,"nctId":696,"briefTitle":697,"officialTitle":697,"acronym":698,"eligibilityCriteria":699,"healthyVolunteers":12,"sex":18,"minAge":268,"maxAge":4,"enrollmentInfo":700,"targetDuration":4,"studyType":215,"phases":4,"briefSummary":702,"conditions":703,"keywords":706,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":707,"lastUpdatePostDateStruct":708,"startDateStruct":710,"completionDateStruct":712,"leadSponsor":714,"locationsCount":4},"100630703","the-cdac-study---cerebral-dysfunction-after-coronary-revascularization-100630703","NCT07491120","The CDAC Study - Cerebral Dysfunction After Coronary Revascularization","CDAC","Inclusion Criteria:\n\n* Criteria for enrollment are age 18 years or more.\n* A candidate for either elective single or multi-vessel CABG or PCI without limits for lesion location, lesion characteristics or complexity, the number of vessels treated, or the number of stents or bypass grafts placed, or the type of bypass grafts.\n* The decision to undergo either CABG or PCI will be made by the treating physician and patient before research study enrollment, and thus, the revascularization decision is not directed by this research protocol.\n\nExclusion Criteria:\n\nPatients will not be enrolled due to:\n\n* Concomitant valve therapy (surgical or transcatheter).\n* Prior CABG or surgical valve repair\u002Freplacement surgery.\n* PCI within 1 year of the study entry procedure.\n* A hybrid revascularization procedure (PCI plus CABG), an untreated carotid artery stenosis of \\>70%, inability to provide informed consent.\n* The inability to perform pre-procedure tablet-based neurocognitive testing.\n* The lack of stated agreement to return for follow-up on-site neurocognitive testing at the prescribed time points.",{"count":701,"type":23},600,"Neurocognitive decline has long been suspected to be a potential long-term complication of coronary artery bypass grafting surgery (CABG), with reports of post-operative cognitive dysfunction by objective testing approaching 15-50% of patients in the year following surgery. To determine the true rate of long-term cognitive dysfunction following CABG compared to percutaneous coronary intervention (PCI or coronary stent placement), we propose a multi-center, two-group, non-randomized study using computer-based customized neurocognitive testing (Cogsate), prior to the procedure and then at 30 days, 1-year and 2-years after revascularization to evaluate cognitive function vital for the maintenance and advancement of professional and personal activities. It is anticipated that the study will document a higher rate of cognitive dysfunction in the CABG group, that the landmark study will provide both the patient and physician with the information necessary to make an informed decision regarding the cognitive risks of CABG versus PCI when faced with the need for coronary revascularization, and that these results will change the clinical practice of recommending CABG as a primary revascularization option for those wishing to preserve cognitive function.",[704,705,30],"CABG","PCI",[704,705,30],"2026-03-19",{"date":709,"type":41},"2026-03-24",{"date":711,"type":23},"2027-01-01",{"date":713,"type":23},"2033-01-01",{"name":715,"class":48},"The Scripps Research Institute",{"id":717,"slug":718,"hasResults":12,"nctId":719,"briefTitle":720,"officialTitle":721,"acronym":4,"eligibilityCriteria":722,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":723,"enrollmentInfo":724,"targetDuration":4,"studyType":24,"phases":726,"briefSummary":727,"conditions":728,"keywords":729,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":739,"lastUpdatePostDateStruct":740,"startDateStruct":742,"completionDateStruct":744,"leadSponsor":746,"locationsCount":49},"100546632","enhancing-attention-and-wellbeing-using-digital-therapeutics-100546632","NCT06397469","Enhancing Attention and Wellbeing Using Digital Therapeutics","Optimizing a Closed-loop Digital Meditation Intervention for Remediating Cognitive Decline and Reducing Stress in Older Adults","Inclusion Criteria:\n\n* 60+ years old (adult)\n* English language fluency\n* owning a smartphone or tablet\n\nExclusion Criteria:\n\n* Under 60 years old (minor)","99 Years",{"count":725,"type":23},4000,[26],"The goals of the proposed research are to first determine the minimal and\u002For optimal dose of a digital intervention required for cognitive enhancement, and then to examine the impact of several potential moderators of treatment effects (i.e., cognitive decline, AD polygenic hazard score, cardiovascular risk, and race\u002Fethnicity). This knowledge gained from his high-impact study with transform the field of cognitive interventions, paving the way for a precision medicine model for cognitive enhancing interventions that improve quality of life for older adults and individuals with cognitive deficits at risk of developing dementia.",[218,519,30],[730,731,464,465,732,733,734,735,736,737,738],"healthy aging","attention","intervention","digital","behavioral","prevention","decline","stress reduction","Quality of life","2026-02-20",{"date":741,"type":41},"2026-02-24",{"date":743,"type":41},"2024-04-01",{"date":745,"type":23},"2029-06",{"name":747,"class":48},"University of California, San Francisco"]